Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled BIBW 2948 BS in Healthy Male Smokers
NCT02216461Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Primary completion
- Apr 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIBW 2948 BS in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically significant findings in vital signs, Number of patients with clinically significant findings in 12-lead electrocardiogram (ECG) and 3 more. Started Jan 2006; status: completed.
02
Drugs
BIBW 2948 BS
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02216461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216461.